TITLE: A Tissue Engineering Approach to Study the Progression of Breast Tumor Metastasis in Bone

Similar documents
CONTRACTING ORGANIZATION: University of California Lawrence Berkeley National Laboratory Berkeley, CA 94720

TITLE: Neural Protein Synuclein (SNCG) in Breast Cancer Progression

TITLE: Dietary Genistein and Prostate Cancer Chemoprevention

CONTRACTING ORGANIZATION: North Eastern Ohio Universities Rootstown OH 44202

TITLE: New Advanced Technology to Improve Prediction and Prevention of Type 1 Diabetes

Fort Detrick, Maryland

TITLE: Evaluation of DNA Methylation as a Target for Intraductal Therapy for Ductal Carcinoma in Situ of the Breast

Award Number: W81XWH TITLE: Regenerative Stem Cell Therapy for Breast Cancer Bone Metastasis

Award Number: W81XWH TITLE: Dietary Fish Oil in Reducing Bone Metastasis of Breast Cancer

CONTRACTING ORGANIZATION: Western Institute For Biomedical Research Salt Lake City, UT

TITLE: 64Cu-DOTA-trastuzumab PET imaging in women with HER2 overexpressing breast cancer

CONTRACTING ORGANIZATION: Sloan-Kettering Institute for Cancer Research New York, NY 10021

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Award Number: W81XWH

TITLE: Enhancing the Anti-Tumor Activity of ErbB Blockers with Histone Deaccetylase (HDAC) Inhibition in Prostate Cancer Cell Lines

TITLE: Role of ADAM15 in Tumor/Endothelial Interactions Prostate Cancer Regression

TITLE: Breast Tumor-Generated Type 1 Collagen Breakdown Fragments Act as Matrikines to Drive Osteolysis

TITLE: Targeting the Immune System s Natural Response to Cell Death to Improve Therapeutic Response in Breast Cancers

CONTRACTING ORGANIZATION: Mount Sinai School of Medicine New York, New York

TITLE: Targeted Eradication of Prostate Cancer Mediated by Engineered Mesenchymal Stem Cells

TITLE: Genes Associated with Food Allergy and Eosinophilic Esophagitis

TITLE: Induction of Ephs/Ephrins-Mediated Tumor Cells-Endothelial Cells Repulsion as an Anti-Cancer Therapeutic Approach

Award Number: W81XWH TITLE: Global Positioning Systems (GPS) Technology to Study Vector-Pathogen-Host Interactions

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Crosstalk Between Cancer Cells and Bones Via the Hedgehog Pathway Determines Bone Metastasis of Breast Cancer

CONTRACTING ORGANIZATION: Regents of the University of Michigan Ann Arbor, MI 48109

Approved for public release; distribution unlimited

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Oxidative Stress, DNA Repair and Prostate Cancer Risk. PRINCIPAL INVESTIGATOR: Hua Zhao, Ph.D.

Sphingosine-1-Phosphate Receptor Subtype 3: A Novel Therapeutic Target of K-Ras Mutant Driven Non-Small Cell Lung Carcinoma

AD (Leave blank) TITLE: Proteomic analyses of nipple fluid for early detection of breast cancer

AD (Leave blank) Award Number: W81XWH TITLE: Targeting Autophagy for the Treatment of TSC and LAM. PRINCIPAL INVESTIGATOR: Elizabeth Henske

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, MD

CONTRACTING ORGANIZATION: Johns Hopkins Bloomberg School of Public Health

TITLE: Investigating the Role of TBX2 in the Inhibition of Senescence in Prostate Cancer

TITLE: Systemic Oncolytic Cytokine HSV Therapy of Prostate Cancer. CONTRACTING ORGANIZATION: Massachusetts General Hospital Boston, MA

Award Number: W81XWH

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

AWARD NUMBER: W81XWH TITLE: Androgen Deprivation Therapy and Cognitive Impairment. PRINCIPAL INVESTIGATOR: Robert N. Pechnick, Ph.D.

TITLE: A PSCA Promoter Based Avian Retroviral Transgene Model of Normal and Malignant Prostate

TITLE: Adipose Estrogen and Increased Breast Cancer Risk in Obesity: Regulation by Leptin and Insulin

TITLE: Investigation of the Akt/PKB Kinase in the Development of Hormone-Independent Prostate Cancer

CONTRACTING ORGANIZATION: Vanderbilt University Medical Center Nashville, TN

TITLE: Identification of New Serum Biomarkers for Early Breast Cancer Diagnosis and Prognosis Using Lipid Microarrays.

TITLE: Effect of COX-2 (PGE2) and IL-6 on Prostate Cancer Bone Mets

Detection of Prostate Cancer Progression by Serum DNA Integrity

Page 1 AWARD NUMBER: W81XWH TITLE: A Novel Pleiotropic Anti-Inflammatory Drug to Reduce ARDS Incidence. PRINCIPAL INVESTIGATOR: Gary Nieman

La Jolla, CA Approved for Public Release; Distribution Unlimited

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

AWARD NUMBER: W81XWH TITLE: Treatment of Pain and Autonomic Dysreflexia in Spinal Cord Injury with Deep Brain Stimulation

TITLE: Properties of Leukemia Stem Cells in a Novel Model of CML Progression to Lymphoid Blast Crisis

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Effect of Reminder Telephone Calls on Mammography Compliance in High Risk

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

CONTRACTING ORGANIZATION: Oregon Health & Science University Portland OR 97239

Award Number: W81XWH TITLE: Characterizing an EMT Signature in Breast Cancer. PRINCIPAL INVESTIGATOR: Melanie C.

TITLE: MicroRNA in Prostate Cancer Racial Disparities and Aggressiveness

TITLE: Selective Oncolytic Therapy for Hypoxic Breast Cancer Cells. CONTRACTING ORGANIZATION: Ordway Research Institute Albany, New York 12208

TITLE: Gulf War Illness Evaluation of an innovative detoxification program

CONTRACTING ORGANIZATION: University of Texas M.D. Anderson Cancer Center Houston, TX 77030

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Award Number: W81XWH TITLE: A Novel Membrane-Permeable, Breast-Targeting, Pro-Apoptotic Peptide for Treatment of Breast Cancer

TITLE: Long Term Outcomes of BRCA1/BRCA2 Mutation Testing. CONTRACTING ORGANIZATION: Georgetown University Washington, DC

TITLE: Overcoming Resistance to Inhibitors of the Akt Protein Kinase by Modulation of the Pim Kinase Pathway

TITLE: TREATMENT OF ENDOCRINE-RESISTANT BREAST CANCER WITH A SMALL MOLECULE C-MYC INHIBITOR

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: The Importance of Autophagy in Breast Cancer Development and Treatment

AWARD NUMBER: W81XWH TITLE: Gulf War Illness as a Brain Autoimmune Disorder. PRINCIPAL INVESTIGATOR: Apostolos Georgopoulos, MD, PhD

Expression and Promoter Methylation of P16INK4A During Estrogen-Induced Mammary Carcinogenesis in the ACI Rat. Omaha, NE

TITLE: Short-Term Exercise and Prostate Cancer Prevention in African American Men. CONTRACTING ORGANIZATION: Howard University Washington DC 20059

TITLE: The Influence of Neuronal Activity on Breast Tumor Metastasis to the Brain

TITLE: Estrogen-DNA Adducts as Novel Biomarkers for Ovarian Cancer Risk and for Use in Prevention

TITLE: Prevention and Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Notch in Pathological Angiogenesis and Lymphangiogenesis

CONTRACTING ORGANIZATION: West Virginia University Morgantown, West Virginia

TITLE: Uncarboxylated Osteocalcin and Gprc6a Axis Produce Intratumoral Androgens in Castration- Resistant Prostate Cancer

TITLE: Prostate Expression Databases: Gene Expression Resources for Comparative Studies of Prostate Carcinogenesis

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Approved for public release; distribution unlimited

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

CONTRACTING ORGANIZATION: Cold Spring Harbor Laboratory Cold Spring Harbor, NY 11724

TITLE: Prazosin for Treatment of Patients With PTSD and Comorbid Alcohol Dependence

Promote Adjustment during Reintegration following Deployment

TITLE: Inhibitors of Histone Deacetylases for Radiosensitization of Prostate Cancer

TITLE: Uncarboxylated Osteocalcin and Gprc6a Axis Produce Intratumoral Androgens in Castration-Resistant Prostate Cancer

CONTRACTING ORGANIZATION: Southern Illinois University School of Medicine, Springfield, IL

TITLE: Harnessing GPR17 Biology for Treating Demyelinating Disease

TITLE: Computerized Tailored Interventions for Behavioral Sequelae of Post-Traumatic Stress Disorder in Veterans

TITLE: HER2/neu Antisense Therapeutics in Human Breast Cancer. CONTRACTING ORGANIZATION: Washington University School of Medicine St.

CONTRACTING ORGANIZATION: Fred Hutchinson Cancer Research Center Seattle, WA 98109

TITLE: "Impact of Obesity on Tamoxifen Chemoprevention in a Model of Ductal Carcinoma in Situ"

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Award Number: W81XWH TITLE: "Longitudinal Study of a Novel Performance-based Measure of Daily Function."

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

CONTRACTING ORGANIZATION: Cleveland Clinic Foundation Cleveland, OH 44195

Transcription:

AD AWARD NUMBER: W81XWH-04-1-0749 TITLE: A Tissue Engineering Approach to Study the Progression of Breast Tumor Metastasis in Bone PRINCIPAL INVESTIGATOR: Mingxin Che, M.D., Ph.D. Daotai Nie, Ph.D. CONTRACTING ORGANIZATION: Wayne State University Detroit, Michigan 48202-3622 REPORT DATE: August 2006 TYPE OF REPORT: Final PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE Form Approved OMB No. 0704-0188 Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. 1. REPORT DATE (DD-MM-YYYY) 2. REPORT TYPE 01-08-2006 Final 3. DATES COVERED (From - To) 30 Jul 2004 29 Jul 2006 4. TITLE AND SUBTITLE 5a. CONTRACT NUMBER A Tissue Engineering Approach to Study the Progression of Breast Tumor Metastasis in Bone 5b. GRANT NUMBER W81XWH-04-1-0749 5c. PROGRAM ELEMENT NUMBER 6. AUTHOR(S) 5d. PROJECT NUMBER Mingxin Che, M.D., Ph.D. and Daotai Nie, Ph.D. E-Mail: mche@dmc.org 5e. TASK NUMBER 5f. WORK UNIT NUMBER 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBER Wayne State University Detroit, Michigan 48202-3622 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR S ACRONYM(S) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT Most patients dying of breast cancer suffer painful bone metastasis. It is our hypothesis that the invasive growth and progression of breast metastatic lesions in bone requires the participation of various constituents from "soil". A reconstitution of such "soil" for the growth of breast metastatic cells will provide tremendous insights into factors critical for breast cancer growth in bone. We will firstly use our basic calcium minerals to reconstitute the mineral part of bone environment and then study the interaction of breast cancer cells with bone minerals. Then we will culture osteoblasts or bone marrow stromal cells on calcium phosphate scaffolds and then study the growth of breast cancer cells in this engineered bone microenvironment. Finally we will xenograft the calcium phosphate scaffolds, filled with cultured breast cancer cells, into athymic mice and study the resultant tumor growth and progression in vivo. The defined approach proposed will enable us to evaluate and define each individual components of bone for their role in the progression of breast bone metastasis. 15. SUBJECT TERMS Breast cancer, bone metastasis, tissue engineering, mouse model 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT a. REPORT U b. ABSTRACT U c. THIS PAGE U UU 7 18. NUMBER OF PAGES 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area code) Standard Form 298 (Rev. 8-98) Prescribed by ANSI Std. Z39.18

Table of Contents Introduction......4 Body.4 Conclusions..6 Reportable Outcomes 6

INTRODUCTION Human breast cancers display a very high frequency of metastasis to bone. The progression of breast bone metastasis is often osteolytic causing a significant deterioration in the quality of life for patients. Various constituents of bone have been postulated to contribute to the progression of breast cancer metastatic lesions in bone. However, study of bone metastasis is hampered by the lack of robotic experimental models. Although animal models involving intracardiac injection of tumor cells or direct injection of tumor cells into tibia are valuable for studying breast bone metastasis, they are complicated and possess too many confounding factors for interpreting results. We propose a defined approach to reverse engineer an environment, which breast cancer cells may encounter during their progression in bones, to study various aspects of breast bone metastasis. In this approach, we will use calcium phosphate crystals, manufactured as a 3-D scaffold, to grow breast cancer cells and study their growth and progression. We will seed and culture breast cancer cells on calcium phosphate scaffold and then study the growth and progression of breast cancer cells in this defined condition. Then we will xenograft the scaffolds, along with breast cancer cells, into mice to study the tumor formation and progression. Our approach can be extended to evaluate the postulated involvement of other constituents of bone, such as bone marrow stromal cells and osteoblasts, in the progression of breast cancer bone metastasis. For example, we can co-culture stromal cells with breast cancer cells in the scaffolds and then xenograft the scaffolds into mice to assess whether the presence of bone marrow stromal cells can promote the growth and progression of breast tumors. We believe our approach can address many unanswered questions regarding breast cancer bone metastasis. To validate our approach, the following proof-of-concept studies are proposed: Aim 1. Study whether calcium phosphate scaffold can directly support the growth and progression of breast cancer in vitro; Aim 2. Study whether or not calcium phosphate scaffold can promote the formation and osteolytic progression of breast tumors in vivo; Aim 3. Study whether osteoblasts and bone marrow stromal cells promote the growth and progression of breast cancer cells in vitro and in vivo. BODY OF REPORT KEY RESEARCH ACCOMPLISHMENT Presentation at 2005 Era of Hope Meeting. Results Task 1. Study whether calcium phosphate scaffold can directly support the growth and progression of breast cancer in vitro. Breast cancers display a very high frequency of metastasis to bone, causing significant deterioration in the quality of life for patients. Various constituents of bone have been postulated to contribute to bone metastasis. However, animal models involving intraosseous or intracardiac injection of tumor cells are complicated and not conducive for interpreting factors critical for bone metastasis. In this study, we attempted to reverse engineer an environment to study various aspects of breast bone metastasis. At the initial stage of proof of concept study, we used calcium phosphate (CaPi) crystals as substrata to grow breast cancer cells. We found that MDA-MB-231 (Figure 1) and MCF-7 cells (Figure 2) can adhere, spread, and grow on CaPi substrate. The survival and growth of breast cancer cells on CaPi substrate required the activity of vacuolar ATPase, as suggested by the study using the inhibitor Bafilomycin A1 (Figure 1 and Figure 2). 4

Fig. 1. Growth of MDA-MB-231 cells on CaPi (Left panel) and inhibition of cell growth by Bafilomycin A1, an inhibitor of vacuolar ATPase. Fig.2. Growth of MCF7 cells on CaPi (Left panel) and inhibition of cell growth by Bafilomycin A1, an inhibitor of vacuolar ATPase (right panel). Task 2. Study whether or not calcium phosphate scaffold can promote the formation and osteolytic progression of breast tumors in vivo. We have performed xenografting the CaPi scaffolds, loaded with MDA-MB-231 cells, into mice. We observed that the presence of CaPi scaffolds irritated mice and mice had to be sacrificed much earlier than planned, making the full assessment of osteolytic progression in vivo more difficult. As mentioned in task 1, we observed that the activities of V-ATPase, which can degrade CaPi to mobilize calcium and phosphate, were required for tumor cell growth on CaPi. Here we further assessed the expression of V-ATPase in breast carcinoma in close proximity of minerals by immunocytochemistry using bone marrow aspirates from breast cancer patients. As shown in Figure 3, V-ATPase was expressed in BCa cells in the proximity of bone matrix. Fig.3. Expression of vacuole ATPase in breast cancer cells in the proximity of bone matrix (Positive staining was indicated by the brownish color as arrowed). 5

Task 3. Study whether osteoblasts and bone marrow stromal cells promote the growth and progression of breast cancer cells in vitro and in vivo. We also cultured bone marrow mesenchymal cells, as part of our eventual goal to reconstitute an artificial bone microenviroment to study bone metastasis. Due to the irritation caused by CaPi scaffolds xenografted, mice had to be sacrificed much earlier than planned, making the full assessment of tumor progression in vivo difficult to conduct. We also evaluated whether breast cancer cells can degrade bone (osteolytic). We measured the mobilization of calcium as an indicator for osteolytic degradation of the scaffold. As shown in Figure 4, MCF-7 cells, and to much greater extent, MDA-MB-231 cells are able to cause significant bone degradation. The results suggest that even in the absence of osteoblasts and bone marrow stromal cells, breast cancer cells can directly initiate osteolytic progression. Fig. 4. Mobilization of calcium from CaPi scaffolds. SUMMARY/CONCLUSIONS: CaPi supported the growth of breast cancer MDA-MB-231 and MCF7 cells. Vacuolar ATPase is expressed in breast carcinoma in bone marrow. Inhibition of ATPase by Bafilomycin A1 reduced cell survival and growth of breast cancer cells on CaPi substrate. Our studies using a tissue engineering approach suggest a potential role of breast cancer cells in directly causing osteolysis in bone marrow. Direct xonografting of CaPi scaffolds s.c. caused skin irritation. Further refinement of the scaffolds is required to use this animal model to define the factors important for breast cancer metastatic progression. REPORTABLE OUTCOMES 6

Review article published. Nie D, Honn KV. Eicosanoid regulation of angiogenesis in tumors. Semin Thromb Hemost. 2004 Feb;30(1):119-25. Abstract published. Krishnamoorthy, S., K. R. Maddipati, D. Nie, and K. V. Honn. 12-Lipoxygenase in hypoxia and hypoxia-induced angiogenesis. Proc. Amer. Assoc. Cancer Res. 45: #3591, 2004. Development of animal models: Yes. 7